CourtneyCrimMD

PubMed

• 5 citations
  Efficacy and safety of GSK3772847 in participants with moderate-to-severe asthma with allergic fungal airway disease: A phase IIa randomized, multicenter, double-blind...
  Chika Akinseye, Courtney Crim, Amy Newlands, David Fairman
  Plos One. 2023-01-01
• 8 citations
  International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials.
  Peter M A Calverley, Fernando J Martinez, Jørgen Vestbo, Christine R Jenkins, Robert Wise
  American Journal of Respiratory and Critical Care Medicine. 2022-07-01
• 6 citations
  Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD.
  Jørgen Vestbo, Grant Waterer, David Leather, Courtney Crim, Nawar Diar Bakerly
  The European Respiratory Journal. 2022-05-01

Journal Articles

• LABA/ICS in COPD patients with CV disease or risk: a factorial analysis of the SUMMIT trial  
  Celli BR, Anderson JA, Brook RD, Calverley PMA, Crim C, Holmes AP, Martinez FJ, Newby DE, Yates JC, Vestbo J, Am J Respir Crit Care Med, 1/5/2018
• Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial  
  Byrd JB, Newby DE, Anderson JA, Calverley PMA, Celli BR, Cowans NJ, Crim C, Martinez FJ, Vestbo J, Yates JC, Brook RD, Eur Heart J, 1/1/2018
• Cardiac troponin I and cardiovascular risk in patients with chronic obstructive pulmonary disease  
  Adamson PD, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Dixon IJ, Martinez FJ, Newby DE, Vestbo J, Yates JC, Mills NL, J Am Coll Cardiol, 1/1/2018
• Beta-blocker therapy and clinical outcomes in patients with moderate COPD and heightened cardiovascular risk: an observational sub-study of SUMMIT  
  Dransfield MT, McAllister DA, Anderson JA, Brook RD, Calverley PMA, Celli BR, Crim C, Gallot N, Martinez FJ, Scanlon PD, Yates JC, Vestbo J, Newby DE, Ann Am Thorac Soc, 1/1/2018
• Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events: A post hoc cohort analysis from the SUMMIT randomized clinical trial  
  Kunisaki KM, Dransfield MT, Anderson JA, Brook RD, Calverley PMA, Celli BR, Crim C, Hartley BF, Martinez FJ, Newby DE, Pragman AA, Vestbo J, Yates JC, Niewoehner DE; S..., Am J Respir Crit Care Med, 1/1/2018
• Predictors of pneumonia on routine chest radiographs in patients with COPD: a post-hoc analysis of two 1-year randomized controlled trials  
  Rubin DB, Ahmad HA, O'Neal M, Bennett S, Lettis S, Galkin DV, Crim C, Int J COPD, 1/1/2018
• Improving the affordability of prescription medications for people with chronic respiratory disease An official American Thoracic Society policy statement  
  Patel MR, Press VG, Gerald LB, Barnes T, Blake K, Brown LK, Costello RW, Crim C, Forshag M, Gershon AS, Goss CH, Han MLK, Lee TA, Sweet S, Gerald JK, Am J Respir Crit Care Med, 1/1/2018
• Fluticasone furoate, vilanterol and lung function decline in patients with moderate COPD and heightened cardiovascular risk  
  Calverley PMA, Anderson JA, Brook RD, Crim C, Gallot N, Kilbride S, Martinez F, Yates J, Newby DE, Vestbo J, Wise R, Celli BR, Am J Respir Crit Care Med, 1/1/2018
• Cardiovascular outcomes with a beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk  
  Brook RD, Anderson JA, Calverley PMA, Celli BR, Crim C, Denvir MA, Magder S, Martinez FJ, Rajagopalan S, Vestbo J, Yates J, Newby DE, Heart, 1/1/2017
• Effect of fluticasone furoate and vilanterol on exacerbations of COPD in patients with moderate airflow obstruction  
  Martinez F, Vestbo J, Anderson JA, Brook RD, Celli BR, Cowans NJ, Crim C, Dransfield M, Kilbride S, Yates J, Newby DE, Niewoehner D, Calverley PMA, Am J Respir Crit Care Med, 1/1/2017
• A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 Mug versus once-daily vilanterol 25 Mug to evaluate the contribution on lung function...  
  Siler TM, Nagai A, Scott-Wilson CA, Midwinter DA, Crim C, Respir Med, 1/1/2017
• A randomized trial of once-daily fluticasone furoate/vilanterol or vilanterol versus placebo to determine effects on arterial stiffness in COPD  
  Bhatt SP, Dransfield MT, Cockcroft JR, Wang-Jairaj J, Midwinter DA, Rubin DB, Scott-Wilson CA, Crim C, Int J COPD, 1/1/2017
• Genetic evaluation of the effect of GLCCI1 rs37973 on corticosteroid response in chronic obstructive pulmonary disease  
  Mosteller M, van den Berge M, Hosking L, Timens W, Hiemstra PS, Crim C, Postma DS, Ghosh S, COPD Research and Practice, 1/1/2017
• Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol in COPD Patients with Moderate Airflow Limitation: the SUMMIT trial  
  Crim C, Calverley PMA, Anderson JA, Holmes AP, Kilbride S, Martinez FJ, Brook RD, Newby DE, Yates JC, Celli BR, and Vestbo J, Respir Med, 1/1/2017
• Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised contro...  
  Vestbo J, Anderson J, Brook RD, Calverley PMA, Celli BR, Crim C, Martinez F, Yates J, Newby DE, Lancet, 1/1/2016
• A genome-wide analysis of the response to inhaled Beta2-agonists in chronic obstructive pulmonary disease  
  Hardin M, Cho MH, McDonald ML, Wan E, Lomas DA, Coxson HO, MacNee W, Vestbo J, Yates JC, Agusti A, Calverley PMA, Celli B, Crim C, Rennard S, Wouters E, Bakke P, Bhatt..., Pharmacogenomics J, 1/1/2016
• Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk  
  Covelli H, Pek B, Schenkenberger I, Scott-Wilson C, Emmett A, Crim C, Int J Chron Obstruct Pulmon Dis, 1/1/2015
• Continuous fat-free mass decline in COPD: fact or fiction?  
  Rutten EPA, Spruitt MA, McDonald M-LN, Rennard S, Agusti A, Celli B, Miller BE, Crim C, Calverley PMA, Hanson C, MacNee W, Franssen FME, Vanfleteren L, Wouters EFM, Eur Respir J, 1/1/2015
• Identification of five COPD subgroups with different prognosis in the ECLIPSE cohort using cluster analysis  
  Rennard SI, Locantore N, Delafont B, Tal-Singer R, Silverman EK, Vestbo J, Miller BE, Bakke P, Celli B, Calverley PMA, Coxson H, Crim C, Edwards LD, Lomas DA, MacNee W..., Ann Am Thorac Soc, 1/1/2015
• One-year change in health status and subsequent outcomes in COPD  
  Wilke S, Jones PW, Mullerova H, Vestbo J, Tal-Singer R, Franssen FME, Agusti A, Bakke P, Calverley PM, Coxson HO, Crim C, Edwards LD, Lomas DA, MacNee W, Rennard SI, Y..., Thorax, 1/1/2015
• Efficacy and safety of fluticasone furoate/vilanterol (50/25 mcg; 100/25 mcg; 200/25 mcg) in Asian patients with chronic obstructive pulmonary disease: a randomized pl...  
  Zheng J, de Guia T, Wang-Jairaj, Newlands AH, Wang C, Crim C, Zhong N, Curr Med Res Opin, 1/1/2015
• Common genetic variants associated with resting oxygenation in chronic obstructive pulmonary disease  
  McDonald M-L, Cho MH, Sorheim IC, Lutz SM, Castaldi P, Lomas DA, Coxson HO, Edwards LD, MacNee W, Vestbo J, Yates JC, Agusti A, Calverley PMA, Celli B, Crim C, Rennard..., Am J Respir Cell Mol Biol, 1/1/2014
• A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects  
  Kempsford R, Allen A, Kelly K, Saggu P, Crim C, Br J Clin Pharmacol, 1/1/2014
• Should we view COPD differently after ECLIPSE? A clinical perspective from the study team  
  Vestbo J, Agusti A, Wouters EFM, Bakke P, Calverley PMA, Celli B, Coxson H, Crim C, Edwards LD, Locantore N, Lomas DA, MacNee W, Miller B, Rennard SI, Silverman EK, Ya..., Am J Respir Crit Care Med, 1/1/2014
• Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality  
  Williams MC, Murchison JT, Edwards LD, Agusti A, Bakke P, Calverley PMA, Celli B, Coxson HO, Crim C, Lomas DA, Miller BE, Rennard S, Silverman EK, Tal-Singer R, Vestbo..., Thorax, 1/1/2014
• Join now to see all

Books/Book Chapters

• Modern Surgical Care: Physiologic Foundations and Clinical Applications 
  Chapter: Physiology of Respiration 
  Page 729 - 737Crim CQuality Medical Publishing, Inc., St. LouisEdition 2nd,1998
• Problems in Critical Care. Prognostic Scoring Systems in the ICU 
  Chapter: The Influence of Respiratory Failure on ICU Patient Outcome. 
  Page 616 - 630Crim CEditors: Farmer JC.J.B. Lippincott Co., Philadelphia1989

Abstracts/Posters

• Soluble receptor for advanced glycation endproducts (sRAGE) is a biomarker of emphysema in the ECLIPSE cohort.
  Duvoix A, Miller BE, Edwards LD, Yates JC, Silverman EK, Celli BR, Calverley PMA, Coxson HO, Crim C, MacNee W, Rennard SI, Vestbo J, Wouters E, Bakke P, Agusti A, Tal-..., American Thoracic Society - 108th International Conference, 1/1/2012
• Comparison of forced oscillation and airflow perturbation lung mechanics in a cohort of ECLIPSE subjects.
  Goldman M, Celli B, Crim C, Tal-Singer R, Eur Respir J, 1/1/2009
• No increase in asthma-related hospitalization following addition of salmeterol to an inhaled corticosteroid in patients with asthma: A meta-analysis.
  Nelson HS, Beasley R, Yancey SW, Kral KM, Edwards LD, Sutton LB, Crim CC, Am J Respir Crit Care Med, 1/1/2007
• Cardiac safety of Ventolin� HFA in children <48 months old.
  Hedrick J, Davis A, Lincourt W, Trivedi R, Ellsworth A, Crim C, J Allergy Clin Immunol, 1/1/2007
• Efficacy of Ventolin� HFA cumulative dosing in children <24 months old.
  Davis A, Lincourt W, Trivedi R, Ellsworth A, Crim C, J Allergy Clin Immunol, 1/1/2007
• Safety of fluticasone propionate HFA in children (<12 years old) with asthma.
  Scott CA, Wu W, Crim C, Proc Amer Thoracic Soc, 1/1/2006
• Pharmacokinetics and pharmacodynamics of inhaled fluticasone propionate in 0.5-11 years old pediatric asthmatic patients.
  Mehta RS, Kunka RL, Daley-Yates PT, Sale ME, Crim CC, Beerahee M, Proc Amer Thoracic Soc, 1/1/2006
• Safety of Ventolin HFA MDI in children birth-<24 months old with symptoms of bronchospasm.
  Davis-Allen A, Lincourt W, Trivedi R, Ellsworth A, Crim C, J Allergy Clin Immunol, 1/1/2006
• A study to evaluate the handling performance of Ventolin HFA MDI with counter in subjects with asthma or COPD.
  Wasserman RL, Locantore NW, Carranza-Rosenweig J, Crim C, Lincourt WR, J Allergy Clin Immunol, 1/1/2006
• A study to evaluate the handling performance of fluticasone propionate/salmeterol HFA MDI with counter in subjects with asthma or COPD.
  Sheth KK, Lincourt WR, Lee BT, Locantore NW, Crim C, Proc Amer Thoracic Soc, 1/1/2005
• Fluticasone propionate HFA improves asthma control in pre-school age children with asthma.
  Sugarman RW, Teper AM, Girardi G, Scott CA, Clements DS, Wu W, Crim C, J Allergy Clin Immunol, 1/1/2005
• Ventolin HFA MDI safety in children 24-<48 months old with symptoms of bronchospasm.
  Allen-Davis A, Lincourt W, Trivedi R, Ellsworth A, Crim C, J Allergy Clin Immunol, 1/1/2005
• Safety profile of fluticasone propionate HFA in pre-school age children with asthma.
  Qaqundah PY, Maspero J, Ceruti E, Scott CA, Clements DS, Wu W, Crim C, J Allergy Clin Immunol, 1/1/2005
• Fluticasone propionate HFA MDI (FP-HFA) provides comparable improvement in asthma control to the CFC MDI formulation (FP-CFC) pre-school age children with asthma.
  Scott C, Kleha J, Wu W, Crim C, Proc Amer Thoracic Soc, 1/1/2005
• Patient satisfaction with fluticasone propionate/salmeterol (FSC) HFA with an integrated dose counter.
  Lincourt WR, Crim C, Sheth KK, Locantore NW, Carranza Rosenzweig JR, Eur Respir J, 1/1/2005
• Real world handling performance of fluticasone propionate/salmeterol HFA MDI with an integrated dose in subjects with asthma or COPD.
  Crim C, Lincourt WR, Sheth KK, Locantore NW, Eur Respir J, 1/1/2005
• Efficacy and safety of fluticasone propionate/salmeterol DISKUS and fluticasone propionate DISKUS and HFA in children.
  Scott C, Wu W, Ellsworth A, Crim C, Eur Respir J, 1/1/2005
• Handling performance and patient satisfaction of a metered dose inhaler (MDI) with integrated dose counter in patients with COPD.
  Crim C, Lincourt WR, Locantore NW, Carranza-Rosenzweig JR, Chest, 1/1/2005
• A composite assessment of pulmonary function, symptoms, and albuterol use provides a useful tool fro assessing asthma severity and response to treatment in children.
  Crim C, Scott CA, Wu W, Am J Respir Crit Care Med, 1/1/2004
• A composite assessment of pulmonary function, symptoms, and albuterol use provides a useful tool for assessing asthma severity and response to treatment in adolescents...
  Crim C, Scott CA, Wu W, Am J Respir Crit Care Med, 1/1/2004
• Comparability of albuterol metered-dose inhaler versus nebulizer in treatment of asthma symptoms in children < 4 years of age.
  Crim C, Lee B, Trivedi R, Ellsworth A, Lincourt W, Ferree M, Am J Respir Crit Care Med, 1/1/2004
• Asthma exacerbations associated with upper respiratory tract infections in asthmatic children under 4 years of age treated with fluticasone propionate.
  Crim C, Trivedi R, Lee B, Wu W, Weeks T, Lincourt W, Am J Respir Crit Care Med, 1/1/2004
• Effects of combination fluticasone propionate and salmeterol (FSC), fluticasone propionate (FP) and montelukast (MON) on FEV1 as a function of pre-treatment reversibil...
  Lincourt WR, Kamada AK, Crim C, Edwards, LD, Am J Respir Crit Care Med, 1/1/2004
• Fluticasone propionate administered via metered-dose inhaler with valved holding chamber and attached face-mask is effective in improving asthma control by producing a...
  Crim C, Scott CA, Maden CL, Wu W, J Allergy Clin Immunol, 1/1/2004
• Fluticasone propionate (FP) was superior to montelukast (MON) in producing at least a 2-step improvement in asthma severity in children 6-12 years of age.
  Lincourt WR, Crim C, Hanson KM, Edwards LD, J Allergy Clin Immunol, 1/1/2004
• Join now to see all

Lectures

• "Massive Hemoptysis" 
  Boston, MA - 1/1/1994
• "Endoscopic Management of Lung Cancer" 
  Las Vegas, NV - 1/1/1988